Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

NCT04397003 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

BIOLOGICAL: Neoantigen DNA vaccine
DRUG: Durvalumab
DEVICE: TDS-IM v2.0 Device
PROCEDURE: Peripheral blood draws

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]